Mike Mensinger Sells 4,378 Shares of Beta Bionics (NASDAQ:BBNX) Stock

Beta Bionics, Inc. (NASDAQ:BBNX) insider Mike Mensinger sold 4,378 shares of the stock in a transaction dated Tuesday, June 2nd. The shares were sold at an average price of $12.61, for a total transaction of $55,206.58. Following the completion of the transaction, the insider directly owned 184,415 shares in the company, valued at approximately $2,325,473.15. This represents a 2.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Beta Bionics Stock Up 11.6%

Beta Bionics stock opened at $13.89 on Friday. The stock has a market cap of $618.94 million, a P/E ratio of -9.20 and a beta of 3.40. Beta Bionics, Inc. has a twelve month low of $8.80 and a twelve month high of $32.71. The company’s 50-day moving average price is $10.88 and its two-hundred day moving average price is $17.21.

Beta Bionics (NASDAQ:BBNX) last announced its earnings results on Tuesday, April 21st. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. Beta Bionics had a negative net margin of 60.27% and a negative return on equity of 23.00%. The company had revenue of $27.63 million for the quarter. Equities analysts anticipate that Beta Bionics, Inc. will post -2.19 earnings per share for the current fiscal year.

Key Stories Impacting Beta Bionics

Here are the key news stories impacting Beta Bionics this week:

• Positive Sentiment: Beta Bionics recently said it is publishing near real-time real-world data on its iLet Bionic Pancreas on a public website, which could support transparency and commercial momentum. Article Title
• Neutral Sentiment: Several insider stock sales were disclosed, but the company said they were made to cover tax obligations related to equity award vesting, making the impact less concerning than discretionary selling.
• Negative Sentiment: Johnson Fistel and Robbins LLP announced investigations into Beta Bionics and its officers over possible securities-law violations tied to investor losses and slower new patient start growth, creating a legal overhang. Article Title

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the stock. Robert W. Baird lowered their target price on shares of Beta Bionics from $28.00 to $14.00 and set a “neutral” rating on the stock in a report on Wednesday, February 18th. Stifel Nicolaus lowered their target price on shares of Beta Bionics from $22.00 to $20.00 and set a “buy” rating on the stock in a report on Wednesday, April 22nd. Weiss Ratings cut shares of Beta Bionics from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, April 21st. Lake Street Capital set a $20.00 target price on shares of Beta Bionics in a report on Wednesday, February 18th. Finally, The Goldman Sachs Group lowered their target price on shares of Beta Bionics from $19.00 to $17.00 and set a “buy” rating on the stock in a report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $19.70.

Institutional Trading of Beta Bionics

Several large investors have recently made changes to their positions in BBNX. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in shares of Beta Bionics during the 1st quarter worth approximately $95,000. Goldman Sachs Group Inc. acquired a new stake in shares of Beta Bionics during the 1st quarter worth approximately $715,000. Woodline Partners LP acquired a new stake in shares of Beta Bionics during the 1st quarter worth approximately $1,530,000. Strs Ohio acquired a new stake in shares of Beta Bionics during the 1st quarter worth approximately $29,000. Finally, Rhumbline Advisers acquired a new stake in shares of Beta Bionics during the 1st quarter worth approximately $158,000.

Beta Bionics Company Profile

Beta Bionics, a clinical-stage medical device company headquartered in Boston, Massachusetts, is focused on revolutionizing the management of type 1 diabetes through automated insulin delivery solutions. The company’s flagship product, the iLet Bionic Pancreas system, is designed to simplify glycemic control by automatically adjusting insulin dosing in response to continuous glucose monitoring data. By integrating advanced algorithmic control with wearable infusion pumps, the iLet aims to reduce the daily burden of diabetes management and improve clinical outcomes for patients.

At the core of Beta Bionics’ offering is its proprietary bionic pancreas software, which can operate in both insulin-only and dual?hormone modes.